Skip to content

  • Development Pipeline

    Development-stage programs in gout and cancer
  • Gout

    First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout

On June 19, 2012, AstraZeneca PLC completed its acquisition of Ardea Biosciences, Inc. Upon completion of the merger, Ardea became a wholly owned subsidiary of AstraZeneca. The total transaction value was approximately $1.26 billion. See Ardea's public filings with the Securities and Exchange Commission for more information.